TTP607 in Refractory Solid Malignancies
|ClinicalTrials.gov Identifier: NCT00939172|
Recruitment Status : Withdrawn
First Posted : July 14, 2009
Last Update Posted : July 31, 2012
The goal of this clinical research study is to find the highest tolerable dose of TTP607 that can be given to patients with a solid tumor or lymphoma. The safety of TTP607 will also be studied.
Researchers will also do pharmacokinetic (PK) testing of TTP607. PK testing measures the amount of a drug in the body at different time points.
|Condition or disease||Intervention/treatment||Phase|
|Advanced Cancers Lymphoma||Drug: TTP607||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label, Phase I, Single Group Assignment Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TTP607 Administered in Cycles of Five Daily One to Four Hour Infusions to Patients With Advanced Refractory Solid Malignancies|
|Study Start Date :||March 2010|
3.3 mg/m^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
- Maximum Tolerated Dose [ Time Frame: End of each 15 day cycle ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00939172
|Study Chair:||Jennifer J. Wheler, MD||UT MD Anderson Cancer Center|